- Zervalx.com
Product website - Package Insert
Zervalx™ is an orally administered prescription medical food for the dietary management of the following patient conditions:- preconception hyperhomocysteinemia; and/or,
- intermediate- to higher- risk pregnancies which require an increased dietary folate intake; and/or,
- hemolytic, megaloblastic, and/or sickle cell anemia complicated by folate deficiency; and/or
- experiencing methotrexate induced plasma hyperhomocysteinemia.
Zervalx™ should always be used under the supervision of a physician.
Product Resources
Zervalx™
Product DescriptionZervalx™, is indicated for the distinct nutritional requirements of preconception and pregnant women who require increased folate concentrations, in the plasma and/or red blood cells (RBC), regardless of MTHFR C677T polymorphism genotype, with particular emphasis, for preconception and pregnant women over 35 years of age, and/or who are associated with intermediate- to higher- risk pregnancies.10,11,12,13, and/or who have preconception hyperhomocysteinemia14,15,16. Zervalx™ can be used prior to conception17,18, throughout pregnancy, the postnatal period19 or while taking oral contraceptives to improve nutritional folate concentrations.20,21
Zervalx™ is indicated for the distinct nutritional requirements of patients, regardless of folate MTHFR 677C→T polymorphism genotype22,23,24; who present with hemolytic, megaloblastic, and/or sickle cell anemia, complicated by folate deficiency25,26,27,28; and/or experience methotrexate induced plasma hyperhomocysteinemia28,29,30,31.
Use with Zervalx™ should always occur under the care of a physician.
* All l-methylfolate references are found on www.zervalx.com/references.
- Metanx®: The active, natural occurring B-vitamins in Metanx® are directly associated with metabolizing homocysteine, a risk factor for vascular disease, and improving the overall health of the blood vessels.
- Diatx®Zn is a medical food indicated for the distinct nutritional requirements of patients under a physician's treatment for hyperhomocysteinemia with particular emphasis for those individuals diagnosed with chronic kidney disease (CKD), end stage renal disease (ESRD) or dialysis.